Search Results
Your search for all items matches 34711 pages
Showing 31051 - 31100Maternal Malignancy Treated During Pregnancy (125 Mothers)
The majority of women with cancer treated during pregnancy had a diagnosis of breast cancer (69 mothers, including 2 twin pregnancies [55%]) or a hematologic malignancy (20 mothers [16%], including 1 mother with acute lymphoid leukemia, 4 with acute myeloid leukemia, 1 with chronic myeloid...
Maternal Cancer During Pregnancy Does Not Appear to Affect Cognitive or General Development in Early Childhood
In a study reported in The New England Journal of Medicine, Frederic Amant, MD, PhD, of University Hospitals Leuven, Belgium, and colleagues in the International Network on Cancer, Infertility, and Pregnancy found that cancer diagnosed during pregnancy did not appear to affect cognitive, cardiac,...
CancerCare® Welcomes Christine Verini, RPh, as Chief Business Development Officer
CancerCare®, a national nonprofit organization providing free, professional support services to anyone affected by cancer, is pleased to welcome Chief Business Development Officer Christine Verini, RPh. In her role, Ms. Verini will serve as a key member of CancerCare’s Executive Leadership Team,...
Children’s Healthcare, Emory Name Douglas Graham, MD, PhD, Director of Aflac Cancer and Blood Disorders Center
Children’s Healthcare of Atlanta and Emory University has announced that William G. Woods, MD, has stepped down as Director of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Chief of Hematology/Oncology/BMT in the Department of Pediatrics at Emory University....
UCSF Receives $5 Million NCI Grant to Integrate Data From Cancer Research Models
The University of California, San Francisco (UCSF) has received a National Cancer Institute grant of $5 million over the next 5 years to lead a massive effort to integrate the data from all experimental models across all types of cancer. The Web-based repository is an important step in moving the...
UPCI Wins $10.9 Million Grant Renewal for Head and Neck Cancer Research
University of Pittsburgh Cancer Institute (UPCI) researchers have received renewal of their head and neck cancer research through the National Cancer Institute’s competitive Specialized Program of Research Excellence (SPORE) program. The 5-year, $10.9 million grant includes a new project to study...
UNC-Chapel Hill Researchers Awarded $11.3 Million for Four Cancer Nanotechnology Projects
University of North Carolina (UNC) at Chapel Hill researchers received an $11.3 million, 5-year grant to conduct multiple studies exploring the use of tiny nanoparticles to create cancer vaccines and improve cancer drug delivery and responses. The grant is the third in a series of awards that the...
Nivolumab and Cabozantinib Improve Outcomes vs Everolimus in Previously Treated Advanced Renal Cell Carcinoma
The CheckMate 025 trial, reported in The New England Journal of Medicine by Robert J. Motzer, MD, and colleagues, showed that treatment with the programmed cell death protein (PD-1) checkpoint inhibitor nivolumab (Opdivo) increased overall survival vs the mTOR inhibitor everolimus (Afinitor) in...
Endocrine Therapy Alone Linked to Low Risk of Breast Cancer Recurrence in Women With a Low-Risk Score on 21-Gene Assay
A prospective validation study of a 21-gene expression assay showed that treatment with endocrine therapy alone in women with hormone receptor–positive, HER2-negative breast cancer who had a low recurrence risk score resulted in low risk of recurrence. All patients included in the study were...
Inconsistent Federal Regulations Undercut U.S. Research Productivity, National Academies’ Report Finds
Ask any U.S. academic investigator whether research is hindered by duplicative or confusing federal regulations, and the answer is usually a resounding “Yes.” Now comes a report written by representatives of research administrators, former federal government officials, and principal...
Many Patients Do Not Accurately Recall Important Colonoscopy Details as Time Lapses
As time lapses, many patients who have undergone a colonoscopy become less and less likely to recall when and where they last had the procedure performed, who the doctor was who performed it, whether polyps were found, and, if so, the number and size of those polyps, according to new study results...
Alternative Therapies: Knowledge Is Power, but Consider the Source
The use of dietary supplements and other complementary and “alternative” therapies by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about complementary therapies can be...
Be a Voice in The Campaign to Conquer Cancer
We’ll provide the resources. You provide the voice. The Campaign to Conquer Cancer is raising $150 million to support a world free from the fear of cancer. Our potential to raise money increases with every new person who learns about our work. We need the most trusted leaders in the oncology...
New: ASCO Answers Fact Sheet for Patients on Blood Test Results
Check out the latest ASCO Answers fact sheet on understanding blood test results. This one-page guide has information on complete blood count, white blood cell count, white blood cell differential, red blood cell count, platelet count, terms to know, and questions to ask the doctor. Download a...
Conquer Cancer Foundation Grants and Awards: Funding Opportunities Now Available
The Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (CCF) is fueling cancer research and pursuing dramatic advances in the diagnosis, prevention, treatment, and cure of all types of cancer. CCF’s Grants and Awards program supports clinical and translational cancer...
Community Research Forum Holds 2015 Annual Meeting, Explores Developments and Strategies in Conducting Clinical Research
ASCO’s Community Research Forum (CRF) held its 2015 Annual Meeting September 20–21 at ASCO Headquarters in Alexandria, Virginia. Over 75 physician investigators, program directors, and research staff attended the meeting, representing a wide range of community-based practices and research sites...
Journal of Clinical Oncology’s Fall Special Series, Journal of Global Oncology’s Inaugural Issue
This fall, the Journal of Clinical Oncology (JCO) presented two special series: “Pediatric Cancer—Progress Through Collaboration” and “Head and Neck Cancer: Recent Advances, Changing Epidemiology, and Future Directions.” The Pediatric Special Series highlighted collaborative efforts that have...
Philip A. Salem, MD, Awarded the FOEDUS Supreme Medal of Excellence
FOEDUS, the Italian Foundation of Culture and Science, awarded the Supreme Medal of Excellence to oncologist Philip A. Salem, MD, Director Emeritus of Cancer Research at Baylor St. Luke’s Medical Center in Houston and President of the Salem Oncology Center at the Texas Medical Center. The...
Important Research in the Palliative Care of Patients With Cancer
The emphasis at this year’s Palliative Care in Oncology Symposium, held earlier this month in Boston, was on patient-centered care throughout the cancer continuum. The meeting attracted more than 650 attendees and included six general sessions featuring best practices in communication,...
Delays in Drug Approval Are Deadly, Highlighting the Need for Improved Regulatory Efficiency
Researchers have determined just how many lives are lost when effective investigational drugs are not approved in a timely manner. These delays in the process of anticancer drug approvals result in thousands of premature deaths each year, according to an analysis presented at the 16th World...
Smoking Cessation Reduces Mortality in Lung Cancer Screening Population
Data from an analysis of lung cancer screening programs in Italy add further evidence that smoking cessation reduces mortality. Heavy smokers screened by low-dose computed tomography (CT) who stopped smoking before or during the screening period had a three- to fivefold reduction in mortality...
MRI Improves Breast Cancer Detection in Women at Average Risk
Magnetic resonance imaging (MRI) screening of women at average risk for breast cancer achieved a mean additional cancer yield of 15.8 cases per 1,000 women, greatly surpassing yields for supplemental digital breast tomosynthesis (1.25 per 1,000) or supplemental ultrasound (4.1 per 1,000). The...
Expert Point of View: William J. Gradishar, MD
Discussant William J. Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, endorsed Dr. Shafaee’s conclusions, while highlighting caution in interpreting the results. “At first blush, it certainly is...
Aromatase Inhibitors May Decrease Risk of Contralateral Breast Cancer in BRCA Mutation–Positive Patients
Given that BRCA1 and BRCA2 mutation carriers have an estimated 40% to 85% lifetime risk of breast cancer and an increased risk of developing contralateral breast cancer, risk reduction in this population remains essential. According to a study presented at the 2015 Breast Cancer Symposium, use of...
Expert Point of View: Clifford Hudis, MD
Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, said the findings suggest there is essentially no meaningful benefit from chemotherapy in the recurrence score low-risk subset. “It is clinically appropriate to offer endocrine therapy...
TAILORx: Chemotherapy Not Necessary for Women With a Low Recurrence Score
The long-awaited first results are in from the TAILORx study, showing that patients with early breast cancer considered at low risk for recurrence can forgo chemotherapy and be treated with endocrine therapy alone.1 “Women with axillary node-negative, estrogen receptor–positive, HER2-negative...
Expert Point of View: Enrique Grande, MD
Enrique Grande, MD, Head of the Endocrine and Genitourinary Tumors Section of the Medical Oncology Service at Ramon y Cajal University Hospital, Madrid, discussed the NETTER-1 and RADIANT-4 studies at the Presidential Session of the 2015 European Cancer Congress. “There is now a stronger rationale...
Treatment Options Expanding for Neuroendocrine Tumors
Patients with advanced neuroendocrine tumors have two promising new treatment options, according to studies that earned spots in the Presidential Session of the 2015 European Cancer Congress, held recently in Vienna, Austria. The phase III studies evaluated the mTOR inhibitor everolimus (Afinitor)...
Expert Point of View: Michael F. Greene, MD, and Dan L. Longo, MD
In an accompanying editorial in The New England Journal of Medicine, Michael F. Greene, MD, Chief of Obstetrics at Massachusetts General Hospital, and Dan L. Longo, MD, Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, mentioned the low odds for both oncologists and...
Chemotherapy/Radiotherapy Safe in Second and Third Trimesters of Pregnancy
Children with in utero exposure to chemotherapy and/or radiation therapy during maternal treatment for cancer had no impairment in cognition, cardiac function, and general early childhood development, according to a study reported at the European Cancer Congress in Vienna, Austria, and published...
Expert Point of View: Luis Paz-Ares, MD
This is the first time we have seen data from the BIRCH trial in these three different cohorts using biomarker expression on tumor cells and immune cells,” said formal discussant Luis Paz-Ares, MD, Professor Medicine at the Hospital Universitario 12 de Octubre, Madrid, Spain. “BIRCH confirms the...
Atezolizumab Makes Inroads in Non–Small Cell Lung Cancer
The anti–PD-L1 (programmed cell death-ligand 1) antibody atezolizumab (formerly known as MPDL3280A) achieved encouraging outcomes in patients with non–small lung cancer (NSCLC) in two different trials: POPLAR1 and BIRCH.2 PD-L1 has emerged as a predictive biomarker for atezolizumab response in both ...
Expert Point of View: Cora N. Sternberg, MD, FACP
Cora N. Sternberg, MD, FACP, Chief of Medical Oncology at San Camillo Forlanini Hospital, Rome, Italy, discussed the implications of the METEOR trial. Everolimus (Afinitor) is considered standard second-line therapy, with a benchmark progression-free survival of 4.9 months in the RECORD-1 trial,...
Phase III METEOR Trial Finds Cabozantinib Improves Progression-Free Survival vs Everolimus in Advanced Renal Cell Carcinoma
Cabozantinib (Cometriq) nearly doubled progression-free survival compared with standard everolimus (Afinitor) therapy in patients with advanced renal cell carcinoma, according to the phase III METEOR trial.1 Additionally, a preplanned interim analysis found an encouraging trend toward overall...
Expert Point of View: Frederic Amant, MD, PhD
Frederic Amant, MD, PhD, Assistant Professor, Staff Gynecologic Oncologist, and Head of the Scientific Section of Gynecologic Oncology at University Hospitals Leuven in Leuven, Belgium, stressed that the study by Lambertini et al is a meta-analysis, not a randomized controlled trial. Nevertheless,...
Ovarian Suppression During Chemotherapy Preserves Fertility in Young Women With Breast Cancer
Several studies have addressed the risks and benefits of ovarian suppression during chemotherapy for breast cancer in women of childbearing age. A new meta-analysis of randomized trials found that it prevented premature ovarian failure and was associated with a higher number of pregnancies post...
Discussing Financial Toxicity With Patients Who Have Cancer
Patient: “Doc, how much are these drugs going to cost me?” Physician: “They are expensive, and you can see our financial counselor to help you understand the costs.” Cancer care is not a black-and-white endeavor, and costs are considered a distasteful subject to be passed over in tactful silence. ...
Expert Point of View: Cora N. Sternberg, MD, FACP
Cora N. Sternberg, MD, FACP, Chief of Medical Oncology at San Camillo Forlanini Hospital in Rome, Italy, formally discussed CheckMate 025 at the Presidential Session of the 2015 European Cancer Congress as well as findings from the METEOR trial of cabozantinib (Cometriq) in metastatic renal cell...
Nivolumab Produces Survival Benefit in Advanced Renal Cell Carcinoma
Patients with advanced renal cell carcinoma treated with nivolumab (Opdivo) were 27% less likely to die than those receiving everolimus (Afinitor), in a planned interim analysis of the open-label phase III CheckMate 025 trial.1 These positive results prompted an early termination of the study by...
FDA Approves First Oncolytic Viral Therapy in the United States
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma...
ASH Honors Aaron J. Marcus, MD, Posthumously With Award for Lifetime Achievement in Hematology
The American Society of Hematology (ASH) will recognize the late Aaron J. Marcus, MD, of Weill Cornell Medical College and the Veterans Affairs New York Harbor Healthcare System with the 2015 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Marcus, who passed away in May 2015,...
National Academy of Medicine Elects New Members
The National Academy of Medicine (NAM), formerly the Institute of Medicine, announced the election of 70 regular members and 10 international members during its Annual Meeting October 19. Election to the Academy is considered one of the highest honors in the fields of health and medicine and...
Multiple Copies of TP53 Tumor-Suppressor Gene Potentially Related to Lower-Than-Expected Cancer Rate in Elephants
A lower-than-expected rate of cancer among elephants could be potentially related to multiple copies of TP53, “a crucial tumor suppressor gene mutated in the majority of human cancers,” according to a study published online by The Journal of the American Medical Association. “Compared with human...
Tamoxifen Use and Access to Fertility-Preservation Options Among Premenopausal Women With Breast Cancer
A multivariable analysis of clinical factors associated with tamoxifen use among premenopausal women with hormone receptor–positive breast cancer showed that fertility preservation was a significant factor and “the only predictor of both noninitiation and early cessation” of tamoxifen. “Among...
ASCO-Endorsed ASTRO Guidelines: Searching for Consensus on Radiotherapy for Endometrial Cancer
Endometrial cancer is the most common gynecologic cancer, but there has been little consensus about the appropriate indications for adjuvant therapy. One reason for the lack of consensus is the absence of randomized studies in endometrial cancer that report an overall survival benefit. This may be...
ASCO Endorses ASTRO Guideline on Postoperative Radiation Therapy for Endometrial Cancer
As reported in the Journal of Clinical Oncology by Larissa A. Meyer, MD, MPH, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) guideline on postoperative radiation therapy for endometrial cancer.1 The ASCO clinical practice guideline...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Shadowed by Cancer
Although genetic testing has not turned up any inherited mutations that might explain the number of cancers that have plagued my immediate family, over the past 15 years, I have lost my father, aunt, and sister to the disease. In 2001, my husband, Wayne, died of acute promyelocytic leukemia, and...
Frances Giles, MB, MD, FRCPI, FRCPath, Appointed Chief of Hematology/Oncology at Northwestern
Francis Giles, MB, MD, FRCPI, FRCPath, has been appointed Chief of the Division of Hematology/Oncology in the Department of Medicine at Northwestern. In his new role, he will continue to advance the division’s clinical, research, and academic pursuits. Dr. Giles joined the faculty of the Division...
Equanimity
The following essay by S. Vincent Rajkumar, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. It was...
